Abstract: The invention concerns a method for the determination of alkaline phosphatase in a sample by optical measurement in which interference by free haemoglobin or blood substitutes is eliminated by means of certain wavelength combinations, a method for eliminating interference caused by free haemoglobin or blood substitutes in a determination of alkaline phosphatase and the use of certain wavelength combinations to eliminate interference by free haemoglobin or blood substitutes.

Abstract: A device for isolating nucleic acids which reduces the transfer of contaminants during nucleic acid isolation methods which is composed of two vessels which are linked by a closing element in which a material that binds nucleic acids is placed. The nucleic acid can for example be bound to the material by tipping the device.

Abstract: The invention concerns the stabilization and amplification of electrochemiluminescence signals in detection methods.

Abstract: The invention concerns a method for the determination of alkaline phosphatase in a sample by optical measurement which is characterized in that a main measurement wavelength of 450±10 nm in combination with the rate blank procedure is used to eliminate haemoglobin interference, a method for eliminating interference by free haemoglobin or blood substitutes and the use of the combination of a main measurement wavelength with the rate blank procedure to eliminate interference by free haemoglobin or blood substitutes in the determination of alkaline phosphatase.

Abstract: The invention concerns polymerase chimeras which are composed of amino acid fragments representing domains and which combine properties of naturally occurring polymerases that are advantageous with regard to a particular application. It has surprisingly turned out that the domains from the various enzymes are active in the chimeras and exhibit cooperative behaviour. In addition the present invention concerns a process for the production of the chimeras according to the invention and the use of these chimeras for the synthesis of nucleic acids e.g. during a polymerase chain reaction. Moreover the present invention concerns a kit which contains the polymerase chimeras according to the invention.

Abstract: A pharmaceutical composition comprising 250-20,000 U of an EPO preparation and 5-20 mg of a Fe(III) complex is disclosed. This pharmaceutical composition is useful in treating anaemias as well or as haemodialysis patients.

Abstract: The invention concerns a method for the photometric analysis of test elements with a detection zone which is stable towards positioning tolerances of the detection zone comprising the following steps: activating the first light source to irradiate a first region of the detection zone and detecting the light reflected from the detection zone or transmitted through the detection zone in order to generate a first detection signal (50), activating the second light source to irradiate a second region of the detection zone which is displaced relative to the first region in the direction of the positioning tolerance and detecting the light reflected from the detection zone or transmitted through the detection zone in order to generate a second detection signal (60), comparing the first and the second detection signal and determining whether the first and/or the second detection signal has been obtained by illuminating an area situated completely on the detection zone.

Abstract: The invention concerns a device for the capillary transport of a liquid between two opposite, essentially planar layers, in which the two layers are arranged parallel to one another at such a distance that there is a capillary-active gap between the two layers, wherein at least one of the two layers contains at least two discrete adjacent parts and capillary-active transport of the liquid is possible beyond the common boundary of the parts that lie in one layer.

Abstract: New dye-polysaccharide and dye-cyclosaccharide conjugates and their use as a diagnostic agent especially for determining the glomerular filtration rate in humans.

Abstract: A fibrinolytically active plasminogen activator of the tissue type, wherein the growth factor (G) domain has been deleted, and wherein also the K1 domain has been deleted and additionally has been modified in one or more of the following sites or region: the sites of amino acid residues 177, 184, 277 and 448 and the F domain, the F domain modification if present being a deletion of part or all of said domain; DNA-sequence comprising a nucleotide sequence coding for said plasminogen activator; expression vector which in a transformed host cell can express said DNA-sequence; host cell transformed using such vector; pharmaceutical composition comprising the fibrinolytically active plasminogen activator; plasminogen activator for use in treating thrombotic disease; a process for the manufacture of such fibrinolytically active plasminogen activator; a process for the treatment of thrombotic disorder; and a process of localizing thrombi while using such plasminogen activator.

Abstract: The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.

Abstract: The combination of erythropoietin and calcium, with or without phosphates, is useful for treating haemochromatoses. A method for treating primary haemochromatoses in a patient involves administering to the patient a combination therapy including an erythropoietin preparation and a calcium preparation, where the erythropoietin preparation and the calcium preparation are each administered from 1 to 5 times weekly. Beneficially, this combination therapy further administers a phosphorus preparation.

Abstract: The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.

Abstract: The invention concerns a process for the production of a polypeptide with suitable glycosylation by culturing eukaryotic cells and isolating the polypeptide from the culture medium or/and the cells. In this process the desired glycosylated polypeptide can be produced recombinantly with the aid of endogenous gene activation or be produced naturally by the cells.

Abstract: System and process for isolating purified biological materials with a collecting unit which has collecting vessels that are accessible from above with a matrix unit in which matrix vessels are arranged in a holder as well as a closure unit which can be placed on the collecting unit to close the collecting vessel. In addition the invention also concerns a system having a collecting unit, a matrix unit, and a closure unit as well as a lysis unit and a waste unit. Moreover a new closure arrangement is disclosed which is suitable for closing vessels in which there is excess pressure.

Abstract: A bioreaction module for biochemical reactions, in particular for cell-free polypeptide biosynthesis, having a housing (1) including a system chamber (12) and a supply chamber (10), wherein the system chamber (12) contains a producing system during the biochemical reaction and the supply chamber (10) contains a supply liquid during the biochemical reaction, and the system chamber (12) and the supply chamber (10) are separated by a semi-permeable membrane (7). The housing (1) comprises a system chamber element (5) and at least one supply chamber element (3) between which the semi-permeable membrane (7) is mounted in such a manner that the system chamber (12) is defined by the system chamber element (5) and the semi-permeable membrane (7) and the supply chamber (10) is defined by the supply chamber element (3) and the semi-permeable membrane (7).

Abstract: The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances.

Abstract: Ready-to-use, aqueous injection solutions containing carvedilol (1-(9H-carbazolyl-4-yloxy)-3-[[(2-(2-methoxyphenoxy)ethyl]-amino]-2-propanol) or its pharmacologically harmless salts which are stable in storage and are well tolerated by veins are disclosed.

Abstract: A blood withdrawal system for withdrawing blood for diagnostic purposes including a lancing device having a housing with an opening and a support surface, and a lancet holder movably mounted in the opening including a lancet and a bearing member that rests on the support surface. The device further includes a trigger unit which, when moved linearly, causes a rotational movement to initiate a lancing process.

Abstract: A method is described for the direct, exponential amplification and sequencing (“DEXAS”) of a DNA molecule from a complex mixture of nucleic acids, wherein truncated DNA molecules as well as DNA molecules of full length are synthesized simultaneously and exponentially between two positions on the said DNA molecule, which initially contains a DNA molecule in a thermocycling reaction, a first primer, a second primer, a reaction buffer, a thermostable DNA polymerase, a thermostable pyrophosphatase (optionally), deoxynucleotides or derivatives thereof and a dideoxynucleotide or derivatives thereof. In a preferred embodiment of the method of the invention, direct sequencing of RNA can be performed using one polymerase having a Tabor-Richardson mutation, or a functional derivative thereof, and reverse transcriptase activity. In a more preferred embodiment of the method of the invention, direct sequencing of RNA can be performed in one step, in one vessel.